To determine whether markers of T cell activation and maturation are independently predictive of the response to potent antiretroviral therapy, the Immunophenotypic Markers and Antiretroviral Therapy study applied a novel data-sharing strategy across 5 Adult AIDS Clinical Trial Group trials that counted naive and activated CD4 + and CD8 + T cells in 324 subjects. Regression models-adjustment for baseline CD4 cell count, human immunodeficiency virus (HIV) RNA, and study-revealed that high pretreatment CD8 + T cell activation predicted virologic failure ( ). Additional models showed the greatest increase in CD4 + T cell counts P p .046 in subjects with highest pretreatment naive CD4 + T cell counts ( ), which was enhanced by high CD4 tent performance across trials as indicators of ART activity, together with the demonstrated relationship between such activity and a reduction in subsequent clinical events, has led to the uniform (including regulatory) acceptance of HIV RNA and CD4 + T cell count as measurements signifying antiretroviral and immunorestorative efficacy, respectively [11, 12] . The goal of the present study was to examine whether naive CD4 + T lymphocytes and activated CD4 + and CD8 + T lymphocytes, as measured by flow cytometry, contribute independent information to HIV RNA load and CD4 cell count in predicting the response to ART. The Immunophenotypic Markers and ART (IMART) study is a cross-protocol analysis of 5 current multicenter Adult AIDS Clinical Trials Group (AACTG) trials of potent ART that assayed these T cell immunophenotypic markers by consensus methods, in subjects who were previously untreated or treated only with nucleosides. Because the timely evaluation of the markers would require access to data from ongoing trials, novel data-sharing conditions were developed to limit the possible negative effect on contributing parent studies.
To determine whether markers of T cell activation and maturation are independently predictive of the response to potent antiretroviral therapy, the Immunophenotypic Markers and Antiretroviral Therapy study applied a novel data-sharing strategy across 5 Adult AIDS Clinical Trial Group trials that counted naive and activated CD4 + and CD8 + T cells in 324 subjects. Regression models-adjustment for baseline CD4 cell count, human immunodeficiency virus (HIV) RNA, and study-revealed that high pretreatment CD8 + 
T cell activation predicted virologic failure (
). Additional models showed the greatest increase in CD4 + T cell counts P p .046 in subjects with highest pretreatment naive CD4 + T cell counts ( ), which was enhanced by high CD4 + P ! .0001 and low CD8 + T cell activation. Total lymphocyte count also predicted a subsequent CD4 + T cell change. These results document the utility of T cell markers in predicting treatment outcome and their potential value for the study and management of HIV-1 infection.
Accelerated development of new drugs for the treatment of HIV-1 infection has been made possible by the validation of 2 essential biomarkers that serve as surrogates for clinical efficacy in antiretroviral trials-CD4 + T lymphocyte counts and plasma HIV-1 RNA concentrations [1] [2] [3] [4] . Together, these markers do not fully explain the benefit of potent antiretroviral therapy (ART) on clinical outcomes, such as AIDS progression and death, as would the ideal biomarker [1, [5] [6] [7] [8] [9] . Still, their relevance to the pathogenesis of HIV infection and disease has been well established in natural history studies [10] . Their consis-tent performance across trials as indicators of ART activity, together with the demonstrated relationship between such activity and a reduction in subsequent clinical events, has led to the uniform (including regulatory) acceptance of HIV RNA and CD4 + T cell count as measurements signifying antiretroviral and immunorestorative efficacy, respectively [11, 12] . The goal of the present study was to examine whether naive CD4 + T lymphocytes and activated CD4 + and CD8 + T lymphocytes, as measured by flow cytometry, contribute independent information to HIV RNA load and CD4 cell count in predicting the response to ART. The Immunophenotypic Markers and ART (IMART) study is a cross-protocol analysis of 5 current multicenter Adult AIDS Clinical Trials Group (AACTG) trials of potent ART that assayed these T cell immunophenotypic markers by consensus methods, in subjects who were previously untreated or treated only with nucleosides. Because the timely evaluation of the markers would require access to data from ongoing trials, novel data-sharing conditions were developed to limit the possible negative effect on contributing parent studies.
SUBJECTS AND METHODS

Patient population and laboratory evaluations.
The IMART data set was created with access to 5 ongoing or recently completed AACTG trials that evaluated potent ART in therapynaive subjects or in those with exposure either to zidovudine or to zidovudine and lamivudine [13] [14] [15] [16] [17] . Institutional review boards approved all protocols; all patients provided written, informed consent. The data set included demographic information, study number, and baseline through week-40 values of T lymphocyte subsets and HIV RNA, measured by quantitative HIV-1 RNA polymerase chain reaction assays (Roche Molecular Systems, lower limit of quantitation 400 or 50 copies/ mL or Nuclisens; Organon Teknika, lower limit of quantitation 100 copies/mL). T lymphocyte subpopulations were enumerated in fresh whole blood, according to AACTG consensus immunophenotyping methods [18] Data-sharing methods and statistical analysis. The following data-sharing conditions were implemented as safeguards to preserve the integrity of ongoing contributing trials: (1) no treatment codes were included in the data set; (2) a week-24 end point was selected for analysis, to prevent compromise of longerterm end points of contributing trials; (3) only associations with predictive factors were examined-no summary data of actual CD4 + T cell or HIV RNA responses are included in the results; (4) subjects' data were randomly excluded, to limit the maximum contribution from any single trial to р50% of the analysis population; (5) no study-specific results are reported.
For the outcome, the complete record closest to week 24 was chosen for inclusion in the data set. Because of the variability in scheduled evaluations and visits across trials, the 24-week followup window after the initiation of potent ART ranged from 12 to 40 weeks; 71% were between weeks 20 and 28. This followup time point is referred to as "week 24" throughout. Values for HIV RNA obtained within 60 days before the initiation of potent ART were averaged on the log 10 scale, to obtain the baseline value; for 5 subjects with pretreatment values below the lower limit of the assay, the value of the lower limit was used.
The prespecified objective was to test the hypothesis that CD4 + and CD8 + T cell subpopulations measured in common in the 5 studies would supplement HIV RNA and CD4 + T cell counts in predicting week-24 responses to potent ART. Rankbased (Spearman's) correlations were used to assess bivariate associations. The Wilcoxon signed rank test was used to assess changes from baseline for continuous variables, and McNemar's test was used to test changes in the proportion of subjects with HIV RNA !1000 copies/mL. Regression models were constructed, using linear regression for changes in CD4 + , CD8 + , and naive CD4 + T cell counts. A censored-data normal-distribution regression for log 10 RNA was used to model the week-24 HIV RNA, which accommodates results below the quantification limits of the assay; the baseline log 10 HIV RNA was included as a covariate [19] . A forward stepwise procedure was used to select variables with statistical and biological importance; no corrections were made for multiple comparisons or for the stepwise selection. Interactions were also investigated (i.e., effect modifiers); when interactions were included in the model, each main effect was also included. A set of 4 indicator variables to represent the 5 contributing studies was included in each model; this essentially adjusted for nucleoside-naive versus nucleoside-experienced subjects, although ACTG 343/879 consisted of both zidovudine-experienced and zidovudine-naive subjects. The amount of variability explained by the covariates in the model was assessed by R
2
; for the censored-data regression model, a generalization of R 2 was used [20] . Sensitivity analyses were also conducted, to assess whether results were consistent in subgroups of subjects. Because subsets of CD4 + and CD8 + T lymphocytes were not measured at early time points (e.g., week 12) in these studies, early changes in these markers could not be examined. With the data-sharing conditions, the available sample size of 324 provided 80% power to detect a correlation of 0.15.
RESULTS
Baseline characteristics and correlations.
The analysis cohort consisted of 324 subjects from 5 AACTG studies. Of the 5 studies, 3 were completed at the outset (ACTG 315, 343/879, and 368/890), 1 has been recently completed (ACTG 384), and 1 is ongoing (ACTG 371; table 1) [13] [14] [15] [16] [17] . Subjects were predominantly male (82%) and white non-Hispanic (56%), with a median age of 37 years (25th-75th percentile, 32-45 years [21] . The proportion of T lymphocytes that expressed activation markers was increased; the median percentage of activated CD4 + and CD8 + T cell subpopulations was 16% and 46%, respectively (normal level, !5%) [21] . The median baseline log 10 HIV RNA was 4.63 (43,000 copies/mL).
Correlations between immunologic markers and HIV RNA at baseline are summarized in P p .068 repeated in the restricted data set of subjects with virologic suppression at week 24, the effects were no longer statistically significant ( and , respectively), although the P p .12 P p .40 baseline naive CD4 T cell count remained highly significant ( and , respectively). P p .0008 P p .002 Effect of TLC and Hgb levels. When TLC and Hgb levels were each added to the model described in table 3, neither was predictive of the week-24 HIV RNA, nor was either predictive when CD4 + T cell count, CD8 + T cell count, and their respective subsets were excluded from the model ( ). When ex-P 1 .15 amined in the models described in table 4, which included CD4 + and naive CD4 + T cell counts, neither was additionally predictive of a change in CD4 + T cell count. However, in a model that included only follow-up week, age, sex, and study, the baseline TLC was found to be predictive of a change in CD4 + T cell counts, with a greater increase in CD4 + T cell count predicted by a lower baseline TLC ( ). After adjusting P p .023 for baseline HIV RNA, but not after adjustment for baseline CD4 cell count, the effect of TLC remained significant (P p and , respectively). In similar assessments as for .028 P p .07 TLC, no apparent effect of Hgb was seen ( ). P 1 .7
DISCUSSION
Our results demonstrate that immunophenotypic markers of T cell activation and maturation, as measured by flow cytometry before the initiation of potent ART, independently distinguish subjects who will achieve the greatest and least favorable virologic and immunologic responses 24 weeks later. As a condition of the original data-sharing strategies described for the present cross-protocol analysis, treatment assignment was not examined, to protect the integrity of ongoing, contributing trials. These constraints notwithstanding, and despite the heterogeneity of regimens used in the 5 studies (table 1) , we observed the characteristic patterns of response to potent ARTnamely, decreases in virus load and increases in CD4 + and naive CD4 + T cell counts paralleled by decreases in CD4 + and CD8 + T cell activation markers, as was described in the contributing studies [13] [14] [15] [16] and studies elsewhere [22] [23] [24] [25] . A significant finding in the IMART study was the demonstration, in multivariate modeling adjusted for HIV RNA, CD4 cell count, and other baseline factors, including study as a proxy for treatment assignment, that a higher baseline level of CD8 + T cell activation predicted a poorer virologic response at week 24; 10 percentage points higher baseline level of CD8 + T cell activation resulted in an HIV RNA that was estimated to be 0.2 log 10 higher 24 weeks later ( ). The model also P p .046 identified a higher baseline HIV RNA, which is a validated prognostic marker, and younger age, which is a probable indicator of less-strict adherence to treatment [26] [27] [28] , as independent predictors of an unfavorable HIV RNA response at week 24, along with a trend toward a lower baseline CD8 + T cell count, which is a possible reflection of the contribution of these cells to virus clearance, as was suggested by the viral dynamics substudy [29] of the contributing trial, ACTG 315 [13] . Consistent with these observations, subjects with a week-24 percentage of CD8 + T cell activation above the median were significantly more likely to have a detectable HIV RNA (у400 copies/mL) at week 24 ( ). P ! .001 The value of CD8 + T cell activation as a natural history marker predictive of disease progression [30, 31] , independent of CD4 + T cell count and HIV RNA [32, 33] , has been well established; so too has its relationship to decreases in CD4 + T cell counts and changes in virus load in untreated patients [34] [35] [36] . This marker is also a sensitive indicator of antiretroviral activity, with declining levels paralleling decreases in virus load [13, 15, 16, 23, 37, 38] . That CD8 + T cell activation might also predict the virologic response to treatment is consistent with results from small descriptive studies [37, 39] and 2 larger ART trials, 1 of which was an IMART parent study [16] . ACTG 890/ 368 identified a trend toward the correlation of higher baseline values of activated CD8 + T cell counts and virologic failure after adjustment for baseline HIV RNAand CD4 cell count [16] ; the Quest study of primary HIV infection found, when controlling for baseline HIV RNA, that a higher baseline activated CD8 + T cell count was marginally predictive of a longer time to virus suppression [38] . To our knowledge, the present investigation is the only one to document that a higher percentage of CD8 + T cell activation is a significant predictor of virologic failure during potent ART, independent of virus load and CD4 cell count, whereas, of interest, a higher CD8 + T cell count trends in the opposing direction, toward predicting virologic success.
Although closely linked, CD8 + T cell activation and HIV RNA were only moderately correlated at baseline; in view of their independent effects on outcome, they likely represent distinct elements of pathogenesis. As shown here and elsewhere [21, 23, 24, 40] , T cell activation can persist despite apparent virologic control during potent therapy, with attendant immunologic consequences [21, 41, 42] . Among individuals with virologic suppression, CD8 + T cell activation may reflect residual viral replication in plasma below the level of detection or in virus reservoirs [43] [44] [45] [46] [47] . Furthermore, considering that only a fraction of HIV virions are infectious [48, 49] , markers of host response may be additionally predictive, because the level of CD8 + T cell activation could reflect that component of the virus load. CD8 + T cell activation could be measuring a functional supplement to HIV-1 RNA quantitation that corresponds to the component of the immune response elicited by viral replication but determined by the host-that is, the immunologic correlate of viral replication. Increased CD8 + T cell activation may also reflect ongoing immune dysregulation secondary to HIV infection, which, in turn, could significantly impair treatment-mediated virologic control as well as immunologic recovery, as our data also indicate.
Greater immune reconstitution at week 24, defined as a greater increase in CD4 + and naive CD4 + T cell counts, was predicted in multivariate modeling by a lower baseline CD4 + T cell count, higher virus load, and longer time receiving therapy, which is consistent with results published elsewhere [24, 50] . Adjusting for these and other factors, including study, we identified a strong, independent, positive effect of baseline naive CD4 + T cell count ( ), the T cell subset that is dispro-P ! .001 portionately affected by HIV-1 infection [51, 52] . This demonstration persuasively supports the results of smaller studies [53] [54] [55] [56] that showed the influence on ART-mediated CD4 + and naive CD4 + T cell reconstitution of the pretreatment-naive CD4 + T cell count as a measurement of thymic and, possibly, extrathymic [57] activity. Collectively, findings point to the interpretation that the nadir naive CD4 + T cell count, like the nadir CD4 + T cell count [58] , is an important determinant of the robustness of immunologic recovery. A new finding in the present study is that the activation status of both CD4 + and CD8 + T cells, although not predictive individually, represent significant positive and negative modifiers, respectively, of the baseline naive CD4 + T cell count in predicting subsequent increases in CD4 + T cell counts-effects that were seen predominantly in individuals who had CD4 + T cell counts 1200 cells/mm 3 . Given the central role of HIV-1-induced immune system activation in driving viral replication, CD4 + T cell loss, and disease pathogenesis [55, [59] [60] [61] [62] [63] [64] [65] [66] , it is not surprising that a higher level of pretreatment CD8 + T cell activation, as a modifier of the effect of naive CD4 + T cell counts, reduced immunologic recovery, a finding that is consistent with our parallel demonstration of the blunting effect by this marker on virologic response. In contrast, the enhancing effect of the baseline level of CD4 + T cell activation may be because the majority of HIV-1 replication occurs in activated CD4 + T lymphocytes [67] [68] [69] . This marker may reflect the cellular burden of infected, entrapped CD4 + T cells in lymphoid tissue or other compartments. Higher levels of CD4 + T cell activation would imply a greater potential for gain when these cells are redistributed during the initial phase of treatment [23-25, 52, 70] . Alternatively, CD4 + T cell activation may simply mirror lymphopenia, as indicated by the strong inverse relationship shown in univariate cross-sectional correlations between baseline CD4 + T cell count and activation, which is indeed stronger than that seen between CD4 + T cell count and baseline HIV RNA, as has been noted by others [71] . In advanced disease, with CD4 + T cell counts !200 cells/mm 3 , immune activation at the highest level, and the naive cell reserve at its lowest levels, the independent influence of these immunophenotypic markers is less apparent, and the baseline CD4 + T cell count, adjusted for baseline HIV RNA, is sufficient to account for the subsequent increase in the CD4 + T cell count. Consistent with baseline predictive models, greater increases in CD4 + T cell counts at week 24 were seen in subjects who had greater decreases in CD4 + T cell activation or in those who had achieved virologic suppression with concomitantly lower CD4 + T cell activation, similar to findings recently reported by Hunt et al. [72] . Taken together, these observations suggest that CD4 + and CD8 + T cell activation inform different aspects of treatment response, with CD4 + T cell activation more directly related to immune reconstitution and CD4 + T cell recovery and CD8 + T cell activation representing an expression of virologic activity and its secondary immunologic consequences, which is consistent with our findings in a smaller study [73] .
IMART marker results, if validated like HIV RNA and CD4 cell count in analyses across trials that include treatment assignment and longer durations of therapy, have several important clinical implications. Together with CD4 cell count and HIV RNA, T cell activation and maturation markers can further accelerate the development of new drugs by serving as eligibility or stratification factors and end points in clinical trials of antiretroviral agents. They also have the potential to inform drug selection and the optimal timing for the start, intensification, or change in ART-decisions that are now almost exclusively driven by CD4 cell-count and virus-load criteria. For example, if a cutoff value was identified for nadir naive CD4 + T cell count that signals irreparable immune-system damage, this value could serve as a threshold for the initiation of ART. Similarly, the failure to normalize to predefined benchmark levels of CD4 + and CD8 + cell activation could trigger adjustments to therapy, ideally before the occurrence of virologic breakthrough or the development of drug resistance. Our observation that the baseline total lymphocyte count predicts subsequent increases in CD4 + T cell count, adjusting for HIV RNA and other factors, corroborates and extends work published elsewhere [74] [75] [76] [77] [78] and has the potential for clinical application supporting the use of routine TLC measurements in settings where multiparameter flow cytometry is unavailable.
The present study has several limitations. The length of followup in IMART was only 24 weeks, to prevent the compromise of later end points in parent trials. Our study was designed to evaluate markers that were common to all of the selected trials; additional key markers, such as naive CD8 + or memory CD4 + T cell counts, were not examined. Because improved treatment strategies may emerge from a better understanding of the mechanisms by which T cell activation and maturation, before and during treatment, influence outcome, it will be important to conduct additional intensive investigations to determine the proportion of the increase in CD4 + T cell count that is composed of activated or resting naive and memory subsets, using moresensitive virus-load assays to relate these findings to the robustness of virologic suppression.
In conclusion, immunophenotypic markers of T cell activation and maturation are valuable prognostic and treatment-response indicators for ART, and they hold promise for application to the design of trials and guiding therapeutic choices to optimize outcome. The IMART study complements and adds new information to its contributing parent studies, thus confirming the usefulness of the developed methodology for cross-protocol marker analysis as a template for future investigations aimed at the timely evaluation of marker data from ongoing trials.
